Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 server

Oncology Letters

Volumn 1, Issue 6, 2010, Pages 1097-1100

  Zhang, Xiu Min ^a   Huang, Yang ^b   Li, Zeng ShanLi ^a   Lin, Hui ^a   Sui, Yan Fang ^a  

^a State Key Laboratory of Cancer Biology   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocyte epitope; HLA A2 A24; MAGE n; Prediction

Indexed keywords

EPITOPE; GLUTAMINYLLEUCYLISOLEUCYLPHENYLALANYLGLYCYLISOLEUCYLGLUTAMYLVALYLVALINE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN N; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; AMINO ACID SEQUENCE; ARTICLE; ARTIFICIAL NEURAL NETWORK; CLIENT SERVER APPLICATION; CYTOTOXIC T LYMPHOCYTE; GENE; HUMAN; INTERNET; MAGE N GENE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NETCTL1 2 SERVER; NUCLEOTIDE SEQUENCE; PREDICTION;

EID: 77957936222     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.193     Document Type: Article

References (17)

1. Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E and Ishikawa T: Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn J Clin Oncol 30: 117-121, 2000.
2. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, CoulieP, Boon T and van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167-175, 1995.
3. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
4. Wu W, Sui YF, Ye J, Li ZS, Guo AL, Yang XW, QU P and ZhangXM: The cloning of tumor-associated gene MAGE in human hepatocellular carcinoma cell line. Chin J Cell Mol Immunol 18: 270-274, 2002.
5. Ming LH, Zhu YR, Harris CC, Wang XH, Wu ZY and SunZT: Association of HLA-A02 genotype with hepatocellular carcinoma in a prevalent area of China. Chin J Immunol 15: 305-310, 1999.
6. Cai SL, Zhao HT, Leng XS, Cheng TH, Gong SY, Peng JR, CongX, Wang Y, Rui JA, Hui YZ, Du RY and Chen WF: Melanoma antigen-3 expression in human hepatocellular carcinoma. Chin J Surg 38: 693-696, 2000.
7. Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, KayserS, Moris A, Wallwiener D, Rammensee HG and Stevanovic S: A MAGE-A1 HLA-A*0201 epitope identified by mass spectrometry. Cancer Res 61: 4027-4077, 2001.
8. Vander Bruggen P, Bastin J, Boon T, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A and Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24: 3038-3043, 1994.
9. Dong HL, Li ZS, Ye J, Qu P, Huang YY, Wu W, Lu SY, ChenGS and Sui YF: Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. Cancer Biol Ther 3: 891-898, 2004.
10. Marchand M, van Baren N, Weynants P, et al: Tumor regression observed in patients with metastic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80: 219-230, 1999.
11. Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K and Murai M: Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic Tlymphocytes. Clin Cancer Res 8: 3885-3892, 2002.
12. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, DielIJ, Pedain C, Oberniedermayr M, Schirrmacher V and UmanskyV: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7: 452-458, 2001.
13. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ and Mackall CL: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 38: 158-164, 2002.
14. Schiavetti F, Thonnard J, Colau D, Boon T and Coulie PG: A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res 62: 5510-5516, 2002.
15. Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanović S and Rammensee HG: Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30: 2216-2225, 2000.
16. Zhang XM, Zhang YF, Huang Y, Qu P, Ma B, Si SY, Li ZS, LiWX, Li X, Ge W, Hu PZ and Sui YF: The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides. Oncol Rep 20: 245-252, 2008.
17. Sidney J, Grey HM, Kubo RT and Sette A: Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17: 261-266, 1996.